Cathepsin D regulates lipid metabolism in murine steatohepatitis by Houben, Tom et al.
  
 University of Groningen
Cathepsin D regulates lipid metabolism in murine steatohepatitis
Houben, Tom; Oligschlaeger, Yvonne; Hendrikx, Tim; Bitorina, Albert V.; Walenbergh, Sofie






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Houben, T., Oligschlaeger, Y., Hendrikx, T., Bitorina, A. V., Walenbergh, S. M. A., van Gorp, P. J., ... Shiri-
Sverdlov, R. (2017). Cathepsin D regulates lipid metabolism in murine steatohepatitis. Scientific Reports, 7,
[3494]. https://doi.org/10.1038/s41598-017-03796-5
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
1Scientific RepoRts | 7: 3494  | DOI:10.1038/s41598-017-03796-5
www.nature.com/scientificreports
Cathepsin D regulates 
lipid metabolism in murine 
steatohepatitis
Tom Houben  1, Yvonne Oligschlaeger1, Tim Hendrikx1,2,3, Albert V. Bitorina1, Sofie M. A. 
Walenbergh1, Patrick J. van Gorp1, Marion J. J. Gijbels1, Silvia Friedrichs4, Jogchum Plat1, 
Frank G. Schaap  1, Dieter Lütjohann4, Marten H. Hofker5 & Ronit Shiri-Sverdlov1
Due to the obesity epidemic, non-alcoholic steatohepatitis (NASH) is a prevalent liver disease, 
characterized by fat accumulation and inflammation of the liver. However, due to a lack of mechanistic 
insight, diagnostic and therapeutic options for NASH are poor. Recent evidence has indicated cathepsin 
D (CTSD), a lysosomal enzyme, as a marker for NASH. Here, we investigated the function of CTSD in 
NASH by using an in vivo and in vitro model. In addition to diminished hepatic inflammation, inhibition 
of CTSD activity dramatically improved lipid metabolism, as demonstrated by decreased plasma 
and liver levels of both cholesterol and triglycerides. Mechanistically, CTSD inhibition resulted in an 
increased conversion of cholesterol into bile acids and an elevated excretion of bile acids via the feces, 
indicating that CTSD influences lipid metabolism. Consistent with these findings, treating Wt BMDMs 
with PepA in vitro showed a similar decrease in inflammation and an analogous effect on cholesterol 
metabolism. Conclusion: CTSD is a key player in the development of hepatic inflammation and 
dyslipidemia. Therefore, aiming at the inhibition of the activity of CTSD may lead to novel treatments to 
combat NASH.
Due to the increasing obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has emerged as the most 
important liver disease in the world1. NAFLD comprises a spectrum of liver diseases ranging from benign hepatic 
steatosis to more advanced liver diseases such as cirrhosis and fibrosis, which eventually might result in liver 
failure and death. The combination of steatosis and inflammation is referred to as non-alcoholic steatohepatitis 
(NASH). NASH is a disease stage that can further progress into such advanced liver diseases, underscoring the 
value of preventing/treating the inflammatory aspect of NAFLD. Currently, the etiology and mechanisms leading 
to obesity-induced liver inflammation are not clear, resulting in the lack of well-defined effective therapies2, 3.
Using mice lacking the low-density lipoprotein receptor (Ldlr−/−), we previously demonstrated a positive 
correlation between hepatic inflammation and cholesterol accumulation in lysosomes of Kupffer cells (KCs)4, 5. 
Moreover, lysosomal enzymes such as cathepsin D (CTSD) are increasingly recognized for their involvement in 
inflammatory responses6, 7. Whereas it was initially believed that proteases such as CTSD were only involved in 
non-specific protein degradation inside acidic lysosomes, research of the past decade has indicated that CTSD has 
a wide spectrum of functions, both of physiological and pathological nature8, 9. Under pathological inflammatory 
conditions, CTSD has been associated with distinct disorders such as rheumatoid arthritis, Alzheimer’s disease, 
atherosclerosis and inflammatory bowel disease (IBD)10–13. Furthermore, recent data also revealed a correlation 
between hepatic inflammation and the activity and expression of CTSD in the liver14–16. Relevantly, plasma CTSD 
levels correlated with different stages of NAFLD17. These data suggest the involvement of lysosomes, and more 
specifically the lysosomal enzyme CTSD, in mediating the inflammatory response in NASH. However, despite the 
established relationship between lysosomes and inflammation as well as the awareness of an association between 
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the lysosomal enzyme CTSD and hepatic inflammation, the exact function of CTSD in the context of NASH has 
not yet been investigated.
In the current study, we hypothesized that proteolytic inhibition of CTSD leads to reduced steatohepatitis. 
To induce NASH, Ldlr−/− mice were put on a high-fat, high-cholesterol (HFC) diet for three weeks. This model 
was chosen due to its close resemblance with a human-like lipoprotein profile combined with the presence of 
hepatic inflammation, thereby serving as a physiological model to study NASH18. To examine whether inhibition 
of CTSD decreases hepatic inflammation, Ldlr−/− mice were injected with pepstatin A (PepA), an inhibitor of 
aspartyl proteases, for three weeks or only in the final week of the experiment. In agreement with our hypothesis, 
inhibition of the proteolytic activity of CTSD reduced hepatic inflammation. Remarkably, proteolytic inhibition 
of CTSD dramatically improved lipid and lipoprotein metabolism, which is demonstrated by decreased plasma 
and liver levels of both cholesterol and triglycerides. Mechanistically, CTSD inhibition resulted in an increased 
conversion of cholesterol into bile acids as well as an elevated excretion of bile acids via the feces, indicating that 
CTSD influences lipid metabolism. Consistent with these findings, treating wildtype (Wt) bone marrow-derived 
macrophages (BMDMs) with PepA showed a similar decrease in inflammation and an analogous effect on cho-
lesterol metabolism. These data demonstrate for the first time a key regulatory role for CTSD in lipid metabolism 
in the development of NASH. Hence, aiming at the modulation of CTSD activity in NASH holds therapeutic 
promise and should be further investigated in the future.
Results
Decreased systemic and hepatic inflammation in Ldlr−/− mice after inhibition of CTSD. To 
elucidate the systemic immune effects of proteolytic inhibition of CTSD, blood leukocyte levels were determined 
via fluorescence-activated cell sorting after two weeks and at the end of the experiment. Administration of PepA 
for one week to Ldlr−/− mice on HFC diet resulted in a significant decrease of blood leukocyte, B and CD4+ T 
cells after 3 weeks (Fig. 1A and Supplementary Fig. S2). Though not significant, similar trends were also observed 
for T cells, monocytes, NK cells, Ly6Chigh monocytes, Ly6cint monocytes, Ly6Clow monocytes and CD8+ T cells, 
confirming the reduced systemic inflammatory phenotype after proteolytic inhibition of CTSD (Fig. 1A and 
Supplementary Fig. S2). In contrast, no statistical differences were observed in blood granulocyte levels between 
the groups (Supplementary Fig. S2).
To determine the effect of the proteolytic inhibition of CTSD on hepatic inflammation, immunohistochemi-
cal stainings were performed on liver sections for the inflammatory cell markers Mac-1, CD3, CD68 and F4/80. 
Quantification of all immunohistochemical stainings showed no effect of one week PepA treatment on hepatic 
inflammation in Ldlr−/− mice on HFC diet at histological level (Fig. 1B–D and Supplementary Table S1). This 
observation was also confirmed by H&E-staining (see Supplementary Fig. S3A,B). Additionally, plasma alanine 
transaminase levels, indicative for liver damage, did not change upon one week PepA treatment (data not shown).
As inflammatory changes at histological level usually require administration of the therapeutic agent for more 
than one week before these effects can be observed19–21, we also performed hepatic gene expression analysis 
on the inflammatory markers tumor necrosis factor alpha (Tnfα), chemokine (C-X-C motif) ligand-2 (Ccl2), 
Caspase1, cluster of differentiation 68 (Cd68), interleukin-12 (Il12) and vascular cell adhesion protein (Vcam). 
As shown in Fig. 1E, Supplementary Fig. S3D and Supplementary Table S1, when Ldlr−/− mice on HFC diet 
were treated with PepA for one week, hepatic gene expression levels of Tnfα, Ccl2, Caspase1, Cd68 and VCAM 
were significantly reduced compared to control-treated Ldlr−/− mice on HFC diet (Fig. 1E). A similar trend was 
also observed for hepatic gene expression of IL12 and for the M2 markers cluster of differentiation 206 (Cd206), 
Early growth response protein 2 (Egr2) and ratio of inducible nitric oxide (iNos) and arginase 1 (Arg1) (see 
Supplementary Fig. 3C and Supplementary Table S1). Accordingly, hepatic protein levels of the inflammatory 
cytokines TNFα and IL12 were also reduced upon PepA administration (see Supplementary Table S1), indicat-
ing CTSD as a contributing compound in evoking the hepatic inflammatory response. Moreover, when injected 
over the total three weeks, Ldlr−/− mice showed a nearly significant decrease of hepatic T cell levels, which was 
combined with an even stronger reduction of hepatic inflammatory markers at gene and protein expression level 
(see Supplementary Table S1). Altogether, these data demonstrate that inhibition of the proteolytic site of CTSD 
in Ldlr−/− mice reduces the development of systemic inflammation and hepatic inflammatory gene expression, 
thereby pointing to a pro-inflammatory role of CTSD.
Improved hepatic lysosomal function after inhibition of intracellular and circulating CTSD is 
linked to hepatic inflammation in Ldlr−/− mice. To investigate the effect of PepA on hepatic lysoso-
mal function in diet-induced hepatic inflammation, plasma and hepatic CTSD activity as well as the activity the 
lysosomal enzyme acid phosphatase (AP) were measured in total liver. Treating Ldlr−/− mice on HFC diet with 
PepA for one week resulted in a striking decrease of plasma CTSD activity compared to control-treated mice 
(Fig. 2A). Furthermore, PepA-treated Ldlr−/− mice on HFC diet demonstrated a reduction in hepatic CTSD 
activity (Fig. 2B). In contrast, one week PepA-treatment did neither affect plasma nor hepatic cathepsin E (CTSE) 
activity (Supplementary Fig. 4A,B). Collectively, these results indicate that PepA is a proteolytic inhibitor of intra-
cellular and circulating CTSD. Of note, while Ldlr−/− mice on a HFC diet showed increased plasma and hepatic 
CTSD activity compared to Ldlr−/− mice on chow diet (Fig. 2A,B), when compared to Wt mice on HFC diet, 
plasma CTSD (and not hepatic CTSD) activity increased in HFC-fed Ldlr−/− mice (data not shown). These data 
suggest that circulating CTSD likely plays the most important role in developing hepatic inflammation.
Subsequently, the activity of acid phosphatase (AP) was measured in the liver. Although total hepatic AP 
activity was similar among all groups, control-treated mice on a HFC diet for 3 weeks showed reduced levels of 
lysosomal AP activity compared to mice on chow diet, confirming lysosomal dysfunction upon HFC diet (see 
Supplementary Fig. S4C,D). In contrast, PepA-treated Ldlr−/− mice on HFC diet demonstrated elevated levels of 
hepatic lysosomal AP activity compared to control mice on HFC diet (see Supplementary Fig. S4D). To confirm 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 3494  | DOI:10.1038/s41598-017-03796-5
these effects on lysosomal function, hepatic gene expression was measured for the lysosomal enzymes cathepsin 
D (Ctsd), cathepsin S (Ctss) and Ap. As shown in Fig. 2C and Supplementary Fig. S4E, hepatic gene expression 
of Ctsd, Ctss and Ap returned to chow levels after inhibition of CTSD, confirming the rebalancing of lysosomal 
function after CTSD inhibition. Additionally, to validate whether plasma CTSD levels correlate with the level 
of hepatic inflammation, plasma CTSD levels were measured. Ldlr−/− mice on an HFC diet showed increased 
levels of plasma CTSD levels, whereas mice that received the PepA treatment, showed reduced plasma CTSD 
levels (Fig. 2D). Moreover, hepatic gene expression levels of the inflammatory markers Tnfα, Ccl2 and Caspase1 
correlated significantly with plasma levels of CTSD (Fig. 2E), underlining the link between hepatic inflammation 
and plasma CTSD levels. Together, these data reveal that proteolytic inhibition of intracellular and circulating 
Figure 1. Parameters of systemic and hepatic inflammation in control- and PepA-injected mice. (A) Absolute 
levels of leukocyte, T cell, monocyte and B cell populations at week 2 and 3 of the experiment. (B) Liver sections 
were stained for infiltrating macrophages and neutrophils (Mac-1), T cells (CD3) and resident monocytes/
macrophages (CD68). Positive cells were counted (infiltrated macrophages/neutrophils and T cells) or scored 
(CD68). (C,D) Representative pictures of the Mac-1 (C) and CD68 staining (D) (original magnification, 
200x). (E) Gene expression analysis of Tnfα, Ccl2, Caspase1 and Cd68. Data are shown relative to control mice 
on chow diet. Error bars represent ± SEM; *indicates p ≤ 0.05 and ***p < 0.001 compared to mice on chow 
diet; #indicates p ≤ 0.05 and ###p < 0.001 compared to control-injected mice on HFC diet by use of two-tailed 
unpaired t test; for FACS n = 4 animals per group and for immunohistochemistry and gene expression n = 8–11 
animals per group.
www.nature.com/scientificreports/
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CTSD improves diet-induced hepatic lysosomal dysfunction, which is connected to hepatic inflammation in 
Ldlr−/− mice.
Improved lipid and lipoprotein metabolism in PepA-treated Ldlr−/− mice on HFC diet. To 
determine whether inhibition of CTSD affects lipid metabolism, plasma and hepatic lipid levels were measured. 
Whereas plasma cholesterol and triglycerides were elevated upon feeding an HFC diet, administration of PepA 
significantly decreased both cholesterol and triglycerides in the plasma (Fig. 3A,B). As shown in the fast protein 
liquid chromatography (FPLC) profiles, the reductions of both lipids were mainly attributed to a decrease in the 
VLDL fraction (see Supplementary Fig. S5A–D). Similar to plasma cholesterol and triglyceride levels, hepatic 
cholesterol and triglyceride levels were also elevated in control-treated Ldlr−/− mice on a HFC diet and decreased 
upon treatment with PepA (Fig. 3C,D). These changes in hepatic lipid levels were confirmed by Oil red O staining 
(Fig. 3E and Supplementary Fig. S5E) and are in line with the changes observed in the relative liver weights of 
these mice (Supplementary Fig. S5F).
To further define the influences of PepA-mediated CTSD inhibition on hepatic lipid metabolism, hepatic 
gene expression analysis was performed on markers involved in lipid homeostasis. Compared to control-injected 
Ldlr−/− mice on HFC diet, PepA administration resulted in reduced gene expression levels of Cluster of differ-
entiation 36 (Cd36), Niemann-Pick C2 (Npc2) and Liver X receptor alpha (Lxrα), suggesting a reduced uptake, 
intralysosomal presence and efflux of cholesterol in these mice respectively (Fig. 3F). In addition, peroxisome 
proliferator-activated receptor gamma (Ppar-γ) expression levels, a lipid-activated transcription factor of genes 
controlling lipid metabolism, were also decreased upon PepA administration, indicating a dramatic improvement 
in lipid homeostasis (Fig. 3F).
As the proteolytic inhibition of CTSD also appeared to influence hepatic cholesterol metabolism, hepatic 
synthesis and degradation of cholesterol were investigated in more detail. Inhibition of CTSD by PepA decreased 
hepatic cholesterol synthesis, as shown by measurements of hepatic desmosterol levels (Fig. 4A). This finding 
was confirmed by gene expression levels of the rate-limiting enzyme for cholesterol synthesis, 3-hydroxy-3-
methyl-glutaryl-Coenzyme A reductase (HmG-CoAR) (Fig. 4B). Besides cholesterol synthesis, also cholesterol 
degradation was affected upon inhibition of CTSD. Specifically, whereas also 27-hydroxcholesterol (27HC; 
see Supplementary Fig. S6A) levels were nearly significantly elevated, the conversion of cholesterol into 7 
alpha-hydroxycholesterol (7αHC) was significantly increased in PepA-injected Ldlr−/− mice on a HFC diet com-
pared to control-injected mice on HFD diet (Fig. 4C). In line, hepatic gene expression levels of the cytochrome 
P450 7A1 (Cyp7a1) enzyme, responsible for this conversion, were elevated in PepA-treated Ldlr−/− mice on a HFC 
diet, corroborating increased cholesterol degradation after inhibition of CTSD (Fig. 4D). Furthermore, whereas 
plasma and hepatic bile acid levels remained unaffected (see Supplementary Fig. S6B and C), PepA-treatment 
increased fecal bile acid (significant) (Fig. 4E) and cholesterol (not significant) levels (Fig. 4F). Overall, these data 
Figure 2. Parameters of lysosomal function in control- and PepA-injected mice. (A,B) Plasma (A) and hepatic 
(B) activity of CTSD. (C) Hepatic gene expression analysis of Ctsd. Data are shown relative to control mice on 
chow diet by use of two-tailed unpaired t test. (D) Plasma levels of CTSD. (E–G) Correlation between plasma 
levels of CTSD and hepatic gene expression of Tnfα, Ccl2 and Caspase1 by Pearson correlation. Error bars 
represent ± SEM. **Indicates p < 0.01 and ***p < 0.001 compared to mice on chow diet; #indicates p ≤ 0.05, 
##p < 0.01 and ###p < 0.001 compared to control-injected mice on HFC diet by use of two-tailed unpaired t test. 
n = 9–11 animals in each group. For correlation analysis, n = 4 animals on chow diet and n = 10 for mice on 
HFC diet.
www.nature.com/scientificreports/
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indicate that inhibition of CTSD activity results in increased bile acid synthesis eventually leading to excretion via 
the feces, thereby indicating an effect of CTSD on lipid metabolism.
Inhibition of the proteolytic function of CTSD reduces inflammation in oxLDL-loaded 
BMDMs. In order to explore the specific role of macrophages on the reduced inflammatory response upon 
CTSD inhibition, bone marrow cells of Wt mice were isolated, differentiated to macrophages and incubated 
with oxLDL for 24 hr. Subsequently, cells were treated with PepA for 4 hr, followed by 4 hr stimulation with 
lipopolysaccharide (LPS). Upon incubation with PepA, cytokine levels of the pro-inflammatory marker TNFα, 
measured in the supernatant of the BMDMs, were significantly reduced compared to carrier (dimethyl sulfoxide 
(DMSO))-treated cells (Fig. 5A, left panel). Additionally, cytokine levels of the anti-inflammatory marker IL10 
increased after PepA treatment (Fig. 5A, right panel), confirming the reduction in inflammation upon PepA 
treatment and the pro-inflammatory properties of CTSD in lipid-induced inflammation (as CTSE activity was 
also here not affected by PepA (see Supplementary Fig. S7). In line, Tnfα gene expression measured in BMDMs 
showed a decrease after PepA treatment. A similar trend was also observed for the expression of Ccl2, but this did 
not reach statistical significance (Fig. 5B, right panel). The aggregated in vitro findings are in line with a reduction 
in hepatic inflammation upon PepA treatment, and by extension a pro-inflammatory action of CTSD.
To study whether the PepA-dependent reduction in inflammation was accompanied by an improvement in 
cholesterol metabolism, gene expression analysis was performed for Cd36, Cyp27a1 and HmG-CoAR. In line with 
the hepatic in vivo gene expression data, cholesterol uptake (Cd36) and synthesis (HmG-CoAR) were reduced, 
though not significant, after PepA treatment in BMDMs. Next, Cyp27a1, the main enzyme responsible for the 
Figure 3. Plasma and hepatic lipids in hyperlipidemic mice with or without PepA-treatment. (A,B) Plasma 
total cholesterol and triglyceride measurements. (C,D) Total hepatic cholesterol and hepatic triglyceride 
measurements. (E) Representative pictures (original magnification, 200x) of the Oil red O staining. (F) Gene 
expression analysis of Cd36, Npc2, Lxrα and Ppar-γ. Gene expression data are shown relative to control mice on 
chow diet. Error bars represent ± SEM; *indicates p ≤ 0.05, **p < 0.01 and ***p < 0.001 compared to mice on 
chow diet; #indicates p ≤ 0.05, ##p < 0.01 and ###p < 0.001 compared to control-injected mice on HFC diet by use 
of two-tailed unpaired t test. n = 9–11 animals for each group analysis.
www.nature.com/scientificreports/
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degradation of cholesterol in macrophages, appeared to be upregulated, indicating higher levels of cholesterol 
degradation in BMDMs (Fig. 5C). Thus, oxLDL-loaded BMDMs demonstrate a reduced inflammatory response 
upon proteolytic inhibition of CTSD, likely caused by an improved cholesterol metabolism.
Discussion
A major impediment to the development of well-defined, effective therapies for NASH has been the lack of under-
standing the mechanisms leading to the inflammatory component of this disorder. In the current study, we show 
for the first time that the lysosomal enzyme CTSD is a key player in the pathogenesis of NASH. Mechanistically, 
our data suggest that the pro-inflammatory function of CTSD is tied to a regulation of general lipid metabolism. 
In addition, we provide evidence for the central role of macrophages in exerting the lipid-induced effects of CTSD 
in the liver. These findings unravel CTSD as a promising, novel target for the treatment of NASH.
While CTSD was shown to have anti-inflammatory properties in the context of neutrophils22, ample evidence 
points towards the pro-inflammatory effects of CTSD. In human intestinal epithelial cells and a mouse model for 
IBD, it was shown that activation of the lysosomal enzyme CTSD contributes to intestinal inflammation12, 23, 24. 
Furthermore, inhibition of CTSD and CTSS reduced cardiovascular inflammation and attenuated atherosclerotic 
lesion progression, reiterating the contribution of cathepsins to pathological inflammatory responses7, 11, 25, 26. 
Notably, in the aforementioned IBD and atherosclerotic studies, the pro-inflammatory effects of CTSD were 
suggested to be derived from macrophages7, 12, 23, 24. Indeed, lysosomal enzymes in macrophages appear to 
play a critical role in withstanding the lipid challenge in obesity-induced inflammatory processes27, 28. In line, 
cytokine release was reduced in oxLDL-loaded BMDMs treated with PepA, substantiating the contribution of 
macrophages to CTSD-mediated hepatic inflammation. Surprisingly, hepatic macrophage levels (indicated by 
CD68 quantification) were not reduced after CTSD inhibition. Potential explanations for this finding might be a 
delayed egress of macrophages from the liver upon resolution of inflammation21 or due to a prolonged half-life of 
macrophages20, 29. Relevantly, while we demonstrate a positive correlation between hepatic CTSD expression and 
hepatic inflammation, Fukuo et al. showed reduced levels of hepatic CTSD in NAFLD patients14. However, these 
Figure 4. Hepatic de novo synthesis and degradation of cholesterol. (A,C) Hepatic concentrations of 
desmosterol (A) and 7 alpha-hydroxycholesterol (7αHC; C). Both values are shown relative to the hepatic 
cholesterol concentrations. (B,D) Gene expression analysis of HmG-CoAR and Cyp7a1. (E,F) Fecal bile acid 
(E) and cholesterol levels (F). Both measurements are relative to mg dry weight of the fecal sample. Gene 
expression data are shown relative to control mice on chow diet. Error bars represent ± SEM; *indicates p ≤ 0.05 
and ***p < 0.001 compared to mice on chow diet; #indicates p ≤ 0.05, ##p < 0.01 and ###p < 0.001 compared to 
control-injected mice on HFC diet by use of two-tailed unpaired t test; n = 11 for each group. DCA, deoxycholic 
acid; CA, cholic acid; CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid; αMCA, α-muricholic acid; 
βMCA, β-muricholic acid.
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patients were not evaluated for the presence of inflammation and, thereby, cannot be used to link hepatic inflam-
mation to reduced CTSD expression. Together, our current observations are in line with a causal relation between 
lipid-induced lysosomal dysfunction in hepatic macrophages and the level of inflammation in the liver15. Thus, 
our data point towards a pivotal role for macrophage-derived CTSD in the development of hepatic inflammation.
Relevantly, proteolytic inhibition of CTSD resulted in reduced cholesterol and triglyceride levels in plasma 
and liver. This finding suggests that the improved NASH-phenotype in PepA-treated Ldlr−/− mice is due to an 
effect of CTSD on lipid metabolism. In agreement with this finding, prevention of the proteolytic activation of the 
lysosomal enzyme acid sphingomyelinase was shown to reduce cholesterol and triglyceride levels in the liver30. 
Therefore, the influence of CTSD on lipid metabolism, as observed in this study, might not be unique to CTSD, 
but could rather be a shared mechanism of several lysosomal enzymes to control lipid homeostasis. In support 
of this concept, a deficiency in the gene encoding for CTSD results in a specific type of Batten disease, a disorder 
which is characterized by the cellular accumulation of lipid-containing residues31, 32.
There is considerable evidence contributing to the concept that a disturbance in bile acid metabolism interferes 
with cholesterol and, by extension, triglyceride metabolism. For example, a deficiency in the enzyme CYP7A1 
was shown to lead to a hypercholesterolemic phenotype33, which is in line with our results that showed the same 
inverse relation between Cyp7a1 and plasma cholesterol levels. Of note, patients with CYP7A1 deficiency were 
also reported to be hypertriglyceridemic. In agreement, triglyceride homeostasis and bile acid metabolism were 
revealed to be closely intertwined by regulation of farnesoid X receptor (FXR) and small heterodimer partner 
(SHP) on sterol regulatory element-binding protein (SREBP-1c), which is a known transcription factor of fatty 
acid and cholesterol synthesis34, 35. Similar to cholesterol levels, plasma and liver triglyceride levels in our study 
were inversely correlated with 7αHC levels, the first precursor of the classical pathway of bile acid formation. In 
addition, hypertriglyceridemia has been associated with increased systemic inflammation36. Therefore, the overall 
observed effects on lipid metabolism in our study might be explained by a direct link between CTSD and bile acid 
metabolism. In agreement with this concept, though bile acids levels in plasma and liver were similar, fecal levels 
were dramatically increased after CTSD inhibition. Therefore, our data indicate that modulation of CTSD has the 
potential to increase bile acid excretion, resulting in reduced lipid levels in hyperlipidemic conditions (Fig. 6).
The observation that both plasma (circulating) and hepatic (intracellular) CTSD activity were decreased after 
PepA inhibition suggests that the results in this study are derived from intra- and extracellular effects of CTSD. 
Figure 5. Gene expression and cytokine levels of oxLDL-loaded bone marrow-derived macrophages (BMDM) 
treated with PepA. (A) TNFα and IL10 cytokine secretion in supernatant of Wt mouse BMDMs, exposed to 
oxLDL for 24 hr and, subsequently, treated with or without PepA (4 hr) and LPS (4 hr). (B,C) Gene expression 
analysis of Tnfα, Ccl2, Cd36, HmG-CoAR and Cyp27a1 measured in Wt mouse BMDMs. Gene expression data 
are shown relative to DMSO-treated BMDMs. All data represent the mean value of three or four independent 
experiments (with n = 13-16 per group). Error bars represent ± SEM; *indicates p ≤ 0.05, **p < 0.01 and 
***p < 0.001 compared to DMSO-treated bone marrow-derived macrophages by use of two-tailed unpaired t 
test.
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Indeed, intracellular CTSD-induced apoptosis was demonstrated to induce inflammation in the liver37. Therefore, 
though the strongest decrease in activity was observed in the circulating fraction of CTSD, the observed effects 
are likely a combination of the modulation of intra- and extracellular CTSD. Furthermore, besides CTSD, PepA 
can also inhibit the aspartyl protease CTSE, renin and pepsin, arguing the specificity for CTSD. Renin- and pep-
sin are proteases found in the kidney (renin) and digestive system (pepsin). As the reductions in inflammation 
were also observed in vitro, it is unlikely that either of them are involved in the observed effects in this study. 
Additionally, CTSE activity was unaffected in plasma, liver and BMDMs after PepA treatment, suggesting that the 
observed effects are mainly related to the inhibition of CTSD. Yet, it cannot be completely excluded that PepA also 
influenced other processes that contributed to the observed inflammatory effects in this study.
Enhancing lysosomal exocytosis in several lysosomal storage diseases strongly reduced substrate accumula-
tion, suggesting a pivotal role for this mechanism in the setting of cellular homeostasis38. In the context of lipid 
storage, exocytosis of lysosomes may be a compensatory mechanism to ‘dump’ undigested lipids into the extracel-
lular space as well as an elegant way to conduct signaling to protect the cell from lipid overload. In line with this 
concept, elevated plasma CTSD levels in mice on HFC diet were diminished after reduction of liver lipid levels. As 
such, the excretion of lysosomal enzymes may be a secondary consequence of a survival mechanism to protect the 
cell from lipid overload. Furthermore, changes in lysosomal pH have been shown to alter processing and secre-
tion of CTSD39. Notably, intracellular accumulation of poorly degradable, oxidized lipid-protein cross-links was 
shown to alter the turnover of CTSD, leading to mistargeting of CTSD into the extracellular space40. These data 
suggest that, by targeting specifically the circulating fraction of CTSD, lipid levels may be adjusted.
In summary, our study elucidates a key role for CTSD in the development of NASH. Our data suggest a novel 
mechanism by which CTSD affects lipid metabolism. Future studies are necessary to determine the exact under-
lying mechanisms explaining the observed effect in this study and whether other lysosomal enzymes possess 
similar effects as CTSD. Taken together, targeting CTSD has the potential to become an auspicious, therapeutic 
strategy for NASH.
Methods
Mice, diet and intervention. Experiments were performed according to the Dutch regulation and 
approved by the Committee for Animal Welfare of Maastricht University. Ldlr−/− mice on a C57BL/6 back-
ground were housed under standard conditions and given free access to food and water. Female 12 week-old 
Ldlr−/− mice were fed either regular chow or a high-fat, high-cholesterol (HFC) diet (SAFE, Augy, France) for 
3 weeks and were divided in three groups (n = 11 for each group). The HFC diet contained 21% milk butter, 
0.2% cholesterol, 46% carbohydrates and 17% casein. To examine whether proteolytic inhibition of CTSD would 
decrease hepatic inflammation, Ldlr−/− mice were injected intraperitoneally with pepstatin A (PepA; 50 µg/g body 
weight; P5318, Sigma, Zwijndrecht, the Netherlands), a proteolytic inhibitor of aspartyl proteases. Mice were 
injected with DMSO (8%) or PepA two times every week. An overview of all experimental groups is depicted in 
Supplementary Fig. S1. Collection of blood and tissue specimens, fluorescence-activated cell sorting (FACS), liver 
histology, plasma alanine transaminase levels (ALT), RNA isolation, cDNA synthesis and qPCR were determined 
as described previously4, 15, 41, 42.
Figure 6. Schematic overview illustrating the proposed by which CTSD participates in the development of 
hepatic inflammation. Based on findings of the current study, increased levels of CTSD lead to a disturbance 
in lipid metabolism, which is known to result in increased plasma cholesterol (hypercholesterolemia) and 
triglyceride (hypertriglyceridemia) levels. Consequently, hypercholesterolemia and hypertriglyceridemia can 
lead to hepatic inflammation.
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Bone marrow-derived macrophages (BMDMs). BMDMs were isolated from the tibiae and femurs 
of C57BL/6 mice. Cells were cultured in RPMI-1640 (GIBCO Invitrogen, Brede, the Netherlands) with 10% 
heat-inactivated fetal calf serum (Bondinco B.V. Alkmaar, the Netherlands), penicillin (100 U/ml), streptomy-
cin (100 µg/ml) and L-glutamine 2 mM (GIBCO Invitrogen, Breda, the Netherlands), supplemented with 20% 
L929-conditioned medium (LCM) for 8–9 days to generate BMDMs. After attachment, macrophages were seeded 
at 350,000 cells per well in 24-well plates and incubated for 24 h with oxLDL (25 µg/ml) or medium (control). 
Afterwards, cells were washed and exposed to PepA (10 µg/ml; dissolved in DMSO) or DMSO (0.06%) for 4 h. 
Next, cells were washed and stimulated with or without LPS (100 ng/ml) for 4 h. Finally, conditioned medium was 
used for enzyme-linked immunosorbent assays and cells were lysed for mRNA expression analysis. All in vitro 
data are the result of at least three independent experiments.
Statistical analysis. Data were statistically analyzed by performing two-tailed unpaired t test and Area 
Under the Curve (AUC) analysis using GraphPad Prism version 6 for Windows. Data were expressed as the mean 
and standard error of the mean (SEM) and were considered significantly different compared to control-treated 
mice on chow diet (*p ≤ 0.05; **p < 0.01; ***p < 0.001) and compared to control-treated mice on HFC diet 
(#p ≤ 0.05; ##p < 0.01; ###p < 0.001). Pearson correlation coefficients (r) and respective p values were calculated to 
assess the statistical significance of the correlation.
Additional explanation is provided in the Supplementary Information.
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